Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The More Life CompanySTU:20MP -2.70% 3-1 Month Momentum % is -7.69% as of Aug. 21, 2026. The stock has 3 warning signs investors should review. Among 1,022 Drug Manufacturers companies, The More Life Company ranks worse than 97847.26% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-21), The More Life Company's 3-1 Month Momentum % is -7.69%.
The industry rank for The More Life Company's 3-1 Month Momentum % or its related term are showing as below:
STU:20MP's 3-1 Month Momentum % is not ranked
in the Drug Manufacturers industry.
Industry Median: -4.385
vs STU:20MP: -7.69
The More Life Company (STU:20MP) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
The More Life Company 3-1 Month Momentum % Related Terms
STU:20MP vs ZTS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, The More Life Company's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The More Life Company 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, The More Life Company's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where The More Life Company's 3-1 Month Momentum % falls into.
The More Life Company (STU:20MP) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The More Life Company (STU:20MP) has a 3-1 Month Momentum % of -7.69% as of Aug. 21, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on The More Life Company and its competitors. According to the industry distribution chart, The More Life Company ranks #999999 out of 1022 companies in the Drug Manufacturers industry.
Is The More Life Company's 3-1 Month Momentum % too high?
The More Life Company's current 3-1 Month Momentum % is -7.69%. Based on the distribution chart, The More Life Company ranks #999999 out of 1022 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does The More Life Company's 3-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, The More Life Company ranks #999999 out of 1022 companies for 3-1 Month Momentum %. This places The More Life Company in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on The More Life Company and its competitors. The More Life Company's current 3-1 Month Momentum % is -7.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The More Life Company stock overvalued right now?
The More Life Company (STU:20MP) has a current 3-1 Month Momentum % of -7.69%. The current 3-1 Month Momentum % is -7.69%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For The More Life Company (STU:20MP), the current 3-1 Month Momentum % is -7.69% as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mountain Valley MD Holdings Inc is a Canada-based company. The firm, along with its subsidiaries, is engaged in implementing its Quicksome oral delivery technologies across a variety of molecules in nutraceutical, vaccine, and pharmaceutical drug applications. The company actively invests in and collaborates on pioneering biotechnologies that have the potential to revolutionize the human health and wellness landscape, drive sustainable increases in plant yields and agricultural farming practices, and broadly support animal husbandry health. The Company is a biotech company focused on advancing solutions to optimize human, animal, and plant health.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:20MP has been successfully added to your 
